Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of intravitreal
ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular
histoplasmosis.